drugset / Trial / NCT04555707
The Maintenance Effect of Enstilar Foam in Combination With Otezla
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label study. Approximately 30 qualified subjects will be enrolled in a study lasting 20 weeks which investigates the effect of Enstilar used in combination with Otezla to treat psoriasis.
Timeline
- Start
- 2020-06-24
- Primary completion
- 2021-06-30
- Completion
- 2021-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcipotriol | Small molecule | — | — |
| Subject | betamethasone dipropionate | Small molecule | — | — |
| Background | Apremilast | Small molecule | 30 mg | Oral |